Navigation Links
Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use
Date:11/23/2009

EXTON, Pa., Nov. 23 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15. The reports assess trial and use of Feraheme, obstacles to use, reasons to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other agents.

While only 8% of Nephrologists report use of Feraheme in chronic kidney disease - non dialysis (CKD-ND) patients and only 4% and 0% report use in peritoneal dialysis (PD) and hemodialysis (HD) patients, respectively, there are a number of Nephrologists "on the verge" of use. Two of the Nephrologists in this study reported that their dialysis units now have a contract with AMAG and they are getting ready to start using Feraheme; others report their dialysis units are considering using the product. A few Nephrologists reported that their offices have just placed orders for Feraheme and they are getting ready to try the product; others are in the midst of researching the economics and deciding whether or not it makes sense to stock Feraheme.

Among those who have used Feraheme, initial impressions are positive, although preliminary. Many have not seen follow up lab results so cannot speak to the efficacy of the product. While most have had positive experiences from a safety perspective, there are some who report concern with the product due to its newness and to some, the large doses and speed of injection present some additional reason for concern. The Nephrology practices that are using Feraheme include both offices that previously did not stock any IV iron as well as those who had been stocking Venofer and/or Ferrlecit. In addition to impacting other IV iron products, Nephrologists expect Feraheme will increase their overall use of IV iron and reduce their use of ESAs. The desire to reduce use of ESAs is particularly high with the recent release of TREAT and the advent of bundling. The next wave of research will be conducted in January at six months post launch.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

CONTACT: Jennifer Robinson of BioTrends Research Group, Inc., +1-610-363-3872, jrobinson@bio-trends.com

SOURCE BioTrends Research Group, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
2. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
3. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
4. RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial
5. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
6. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
7. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
8. Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
11. Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , January 24, 2017 The global  active ... 239.8 billion by 2025, based on a new report by Grand View ... is projected to drive the market over the forecast period. Advancements in ... also estimated to boost growth.  Continue Reading ... ...
(Date:1/24/2017)... Aptuit, LLC, hat heute den ... Massachusetts General Hospital (MGH) unter Leitung von Dr. ... Identifizierung und Validierung neuartiger Targets in gramnegativen Bakterien.  Aptuit ... von Antibiotika bei der Behandlung schwerer Infektionen entgegenwirken können. ... ...
(Date:1/24/2017)... YORK , Jan. 23, 2017 Laboratory ... the global use of mass spectrometry in both clinical ... current ,MS analysis, global market size of $6.8 billion ... the next four years, profiles the use of mass ... encompassing 21 countries. This study investigated growth in the ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... ... “Choosing Wisdom-Solomon’s Proverbs Reclaimed”: an inspiring collection of ... anger, and common sense. , “Choosing Wisdom-Solomon’s Proverbs Reclaimed” is the creation ... September of 1983, they flew to Haiti to focus on missions work. During ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... to improve the connection with God. “Spiritual Vitamins: A Spiritual Energy Booster” is ... by Christian Faith Publishing, Mathai Yohannan’s new book engages the mind and spirit ...
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: a ... Balances” is the creation of published author, Pastor Bernard J. Weathers, pastor of Word ... bachelor degree in religious education and a master degree in theology. , ““The Octagon ...
(Date:1/24/2017)... Milford, PA (PRWEB) , ... January 24, 2017 ... ... want breast implants, a new scientific article suggests that autologous fat ... procedure for achieving larger breasts naturally, without breast implants. , Cosmetic Surgeon ...
(Date:1/24/2017)... ... 23, 2017 , ... The Pharmacy and Medically Underserved Areas ... original co-sponsorship of nearly one-quarter of the U.S. House of Representatives. The Senate ... Drug Stores (NACDS) strongly backs the legislation. , “NACDS thanks for their leadership ...
Breaking Medicine News(10 mins):